In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients | Zendy

K. V. I. Rolston | Zendy; D H Ho | Zendy; Barbara LeBlanc | Zendy; Gerald P. Bodey | Zendy

Open Access

In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients

Author(s) -

K. V. I. Rolston,

D H Ho,

Barbara LeBlanc,

Gerald P. Bodey

Publication year - 1987

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.31.1.102

Subject(s) - enoxacin , ciprofloxacin , pseudomonas aeruginosa , microbiology and biotechnology , enterobacteriaceae , in vitro , antibacterial agent , gram negative bacteria , biology , antibiotics , bacteria , escherichia coli , ofloxacin , biochemistry , genetics , gene

The in vitro activity of S-25930 and S-25932, two new 4-quinolones, against 450 aerobic gram-negative organisms isolated from cancer patients was evaluated and compared with the activity of ciprofloxacin, enoxacin, difloxacin (A-56619), and A-56620. Both agents inhibited most members of the family Enterobacteriaceae at concentrations of less than or equal to 2.0 micrograms/ml, but their activity against Pseudomonas aeruginosa was inferior to that of other quinolones. Although considerably less active than ciprofloxacin and A-56620, S-25930 was frequently two- to eightfold more active than S-25932 and was comparable to difloxacin and enoxacin against most isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research